Phase I dose escalation study for optimizing prescribed mucosa dose in BNCT for head and neck cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 20H03631
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Southen Tohoku Research Institute for Neuroscience
• Principal Investigator: Takai Yoshihiro 一般財団法人脳神経疾患研究所, 南東北BNCT研究センター, センター長 (50107653)
• Co-Investigator(Kenkyū-buntansha): 佐藤 まり子 一般財団法人脳神経疾患研究所, 南東北BNCT研究センター, 医長 (30645263) ; 廣瀬 勝己 一般財団法人脳神経疾患研究所, 南東北BNCT研究センター, 診療所長 (60623767) ; 加藤 貴弘 福島県立医科大学, 保健科学部, 教授 (90778804)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 頭頸部癌 / 放射線治療 / BNCT

Outline of Final Research Achievements

A phase I dose escalation study for dose optimization for locoregional recurrent squamous cell carcinoma of the head and neck was conducted. Treatment was selected at the lowest dose of 12/15/18 Gy-Eq as the pharyngolaryngeal mucosa dose prescription, with a minimum tumor dose of 25 Gy-Eq or higher. The primary endpoint was the frequency of acute adverse events within 90 days from the date of BNCT. The enrollment/patients were 25 in total (28 lesions), and acute adverse events greater than G/3 were stomatitis in 5 patients (13%), hyperamylasemia G3 in 8 patients (21%), and G4 in 8 patients (21%). It is likely to be concluded that dose-increasing BNCT can be safely performed.

Free Research Field

放射線治療

Academic Significance and Societal Importance of the Research Achievements

本研究によりBNCTの適正な線量が決定され、有効性がより高められれば、これらのPSの不良な患者に対する治療にも、さらにPSの良好な患者に対してはこれまでにない、より有効な治療が可能となる。